Shirin Hasan1, Michael J Mosier1, Andrea Szilagyi2, Richard L Gamelli1, Kuzhali Muthumalaiappan3. 1. Department of Surgery, Loyola University Chicago, Health Sciences Division, Maywood, IL; Burn and Shock Trauma Research Institute, Loyola University Chicago, Health Sciences Division, Maywood, IL. 2. Burn and Shock Trauma Research Institute, Loyola University Chicago, Health Sciences Division, Maywood, IL. 3. Department of Surgery, Loyola University Chicago, Health Sciences Division, Maywood, IL; Burn and Shock Trauma Research Institute, Loyola University Chicago, Health Sciences Division, Maywood, IL. Electronic address: kmuthu@luc.edu.
Abstract
BACKGROUND: Anemia of critical illness is resistant to exogenous erythropoietin. Packed red blood cells transfusions is the only treatment option, and despite related cost and morbidity, there is a need for alternate strategies. Erythrocyte development can be divided into erythropoietin-dependent and erythropoietin-independent stages. We have shown previously that erythropoietin-dependent development is intact in burn patients and the erythropoietin-independent early commitment stage, which is regulated by β1/β2-adrenergic mechanisms, is compromised. Utilizing the scald burn injury model, we studied erythropoietin-independent late maturation stages and the effect of β1/β2, β-2, or β-3 blockade in burn mediated erythropoietin-resistant anemia. METHODS: Burn mice were randomized to receive daily injections of propranolol (nonselective β1/β2 antagonist), nadolol (long-acting β1/β2 antagonist), butoxamine (selective β2 antagonist), or SR59230A (selective β3 antagonist) for 6 days after burn. Total bone marrow cells were characterized as nonerythroid cells, early and late erythroblasts, nucleated orthochromatic erythroblasts and enucleated reticulocyte subsets using CD71, Ter119, and Syto-16 by flow cytometry. Multipotential progenitors were probed for MafB expressing cells. RESULTS: Although propranolol improved early and late erythroblasts, only butoxamine and selective β3-antagonist administrations were positively reflected in the peripheral blood hemoglobin and red blood cells count. While burn impeded early commitment and late maturation stages, β1/β2 antagonism increased the early erythroblasts through commitment stages via β2 specific MafB regulation. β3 antagonism was more effective in improving overall red blood cells through late maturation stages. CONCLUSION: The study unfolds novel β2 and β3 adrenergic mechanisms orchestrating erythropoietin resistant anemia after burn, which impedes both the early commitment stage and the late maturation stages, respectively.
BACKGROUND:Anemia of critical illness is resistant to exogenous erythropoietin. Packed red blood cells transfusions is the only treatment option, and despite related cost and morbidity, there is a need for alternate strategies. Erythrocyte development can be divided into erythropoietin-dependent and erythropoietin-independent stages. We have shown previously that erythropoietin-dependent development is intact in burn patients and the erythropoietin-independent early commitment stage, which is regulated by β1/β2-adrenergic mechanisms, is compromised. Utilizing the scald burn injury model, we studied erythropoietin-independent late maturation stages and the effect of β1/β2, β-2, or β-3 blockade in burn mediated erythropoietin-resistant anemia. METHODS: Burn mice were randomized to receive daily injections of propranolol (nonselective β1/β2 antagonist), nadolol (long-acting β1/β2 antagonist), butoxamine (selective β2 antagonist), or SR59230A (selective β3 antagonist) for 6 days after burn. Total bone marrow cells were characterized as nonerythroid cells, early and late erythroblasts, nucleated orthochromatic erythroblasts and enucleated reticulocyte subsets using CD71, Ter119, and Syto-16 by flow cytometry. Multipotential progenitors were probed for MafB expressing cells. RESULTS: Although propranolol improved early and late erythroblasts, only butoxamine and selective β3-antagonist administrations were positively reflected in the peripheral blood hemoglobin and red blood cells count. While burn impeded early commitment and late maturation stages, β1/β2 antagonism increased the early erythroblasts through commitment stages via β2 specific MafB regulation. β3 antagonism was more effective in improving overall red blood cells through late maturation stages. CONCLUSION: The study unfolds novel β2 and β3 adrenergic mechanisms orchestrating erythropoietin resistant anemia after burn, which impedes both the early commitment stage and the late maturation stages, respectively.
Authors: Diamantis G Konstantinidis; Suvarnamala Pushkaran; James F Johnson; Jose A Cancelas; Stefanos Manganaris; Chad E Harris; David A Williams; Yi Zheng; Theodosia A Kalfa Journal: Blood Date: 2012-03-28 Impact factor: 22.113
Authors: Yoshio Katayama; Michela Battista; Wei-Ming Kao; Andrés Hidalgo; Anna J Peired; Steven A Thomas; Paul S Frenette Journal: Cell Date: 2006-01-27 Impact factor: 41.582
Authors: Ines G Alamo; Kolenkode B Kannan; Letitia E Bible; Tyler J Loftus; Harry Ramos; Philip A Efron; Alicia M Mohr Journal: J Trauma Acute Care Surg Date: 2017-04 Impact factor: 3.313
Authors: K N Williams; A Szilagyi; P Conrad; M Halerz; A R Kini; Y Li; R L Gamelli; R Shankar; K Muthumalaiappan Journal: J Burn Care Res Date: 2013 Jan-Feb Impact factor: 1.845
Authors: Shirin Hasan; Nicholas B Johnson; Michael J Mosier; Ravi Shankar; Peggie Conrad; Andrea Szilagyi; Richard L Gamelli; Kuzhali Muthumalaiappan Journal: Am J Physiol Cell Physiol Date: 2016-12-28 Impact factor: 4.249
Authors: Tina L Palmieri; Daniel M Caruso; Kevin N Foster; Bruce A Cairns; Michael D Peck; Richard L Gamelli; David W Mozingo; Richard J Kagan; Wendy Wahl; Nathan A Kemalyan; Joel S Fish; Manuel Gomez; Robert L Sheridan; Lee D Faucher; Barbara A Latenser; Nicole S Gibran; Robert L Klein; Lynn D Solem; Jeffrey R Saffle; Stephen E Morris; James C Jeng; David Voigt; Pamela A Howard; Fred Molitor; David G Greenhalgh Journal: Crit Care Med Date: 2006-06 Impact factor: 7.598
Authors: Elizabeth S Miller; Camille G Apple; Kolenkode B Kannan; Zackary M Funk; Philip A Efron; Alicia M Mohr Journal: Am J Surg Date: 2020-07-25 Impact factor: 2.565
Authors: Julia Walczak; Corinne Bunn; Pravesh Saini; Yuk Ming Liu; Anthony J Baldea; Kuzhali Muthumalaiappan Journal: J Burn Care Res Date: 2021-03-04 Impact factor: 1.845
Authors: Russell B Hawkins; Steven L Raymond; Julie A Stortz; Hiroyuki Horiguchi; Scott C Brakenridge; Anna Gardner; Philip A Efron; Azra Bihorac; Mark Segal; Frederick A Moore; Lyle L Moldawer Journal: Front Immunol Date: 2018-07-02 Impact factor: 7.561